295 results about "Fluconazole" patented technology

The present invention refers to a treatment for mixed infectious diseases in the human reproductive system, wherein an association of compounds containing fluconazole and either tinidazole is used, the same being associated in doses lower to those commonly used therapeutically. The combination has proven to be highly efficacious and shown a good degree of tolerance.

This invention relates to a method of treating otitis externa using a topical combination medication, including one or more antifungal agent such as, for example fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, caspofungin, micafungin, terbinafine, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, econazole, enilaconazole, miconazole, oxiconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), nystatin, pimaricin, griseofulvin, ciclopirox, haloprogin, tolnaftate, and undecylenate and one or more antibacterial agent such as neomycin sulfate, polymyxin B sulfate, colistin sulfate, gentamycin, tobramycin, chloramphenicol, Ciprofloxacin, Ofloxacin, a penicillin compound, a cephalosporin compound, a macrolide compound, a fluoroquinolone compound, streptomycin, or kanamycin.

Antimicrobial and contraceptive compositions and methods which prevent and/or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and/or reduce the risk of pregnancy are provided. The compositions contain (1) a matrix-forming agent, (2) a bio-adhesive agent, (3) a buffering agent, (4) optionally a humectant, (5) optionally a preservative, and (6) water; wherein the composition is suitable for application within the vagina; wherein the compositions form a semisolid matrix on contact with ejaculate (thereby trapping ejaculated microbes and spermatozoa); wherein the composition causes hardening of cervical mucus (thereby decreasing the probability of sperm entry); wherein the composition forms a bio-adhesive layer over vaginal surfaces (thereby preventing or reducing the risk of contact of STD-causing microbes with the vaginal surfaces); wherein the composition maintains an acidic vaginal pH of less than about 5 in the presence of semen ejaculated from the male; and wherein the composition does not significantly impair the natural microbiological balance within the vagina. The antimicrobial and contraceptive compositions may also contain additional antimicrobial and/or contraceptive agents (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2SO4-modified mandelic acids, povidone iodine, itraconazole, ketoconazole, metronidazole, clotrimazole, fluconazole, teraconazole, miconazole, tinidazole, iconazole, chloramphenicol, nystatin, cyclopiroxolamine, and the like).

Disclosed is a prescription for liquid status of fluconazole and its preparation, wherein the prescription comprises Fluconazole and medicinal findings, the medicinal findings include diluent (orsolvent), anti-oxidant agent and suspension auxiliary agent, the diluent (orsolvent) includes two types of oil-soluble and water-soluble. The liquid form Fluconazole prepared by the two types of diluent (orsolvent) can be prepared into the dosage forms of capsule, liquid type hard capsule and drop pill.

The invention relates to application of an effective part of a cockroach extract in preparing a drug for inhibiting fungus growth, and particularly relates to application of an effective part obtained by refining a crude cockroach extract through macroporous adsorption resin in the aspect of preparing a drug capable of resisting fungal infection. The effective part is refined from a fresh or dried Periplaneta americana L. polypide product through alcohol and water extraction, macroporous adsorption resin column chromatography and alcohol solvent elution, and has an obvious inhibition effect on the growth activity of candida albicans and a fungus growth inhibition capacity 80 times higher than that of fluconazole and 5-fluorocytosine and 800 times higher than that of amphotericin. The effective part of the cockroach extract can be prepared into forms, such as a hydrogel, a frothy gel, a cataplasm, freeze-dried powder, a water aqua, an aerosol, a suppository, a film, an external liniment, an ointment and the like, and is used for preparing pharmaceutical preparations for preventing and curing fungal infection, medical appliances and daily-use chemical products.

The invention relates to the technical field of medicaments, in particular to novel application of kaempferol as a synergist of anti-fungal medicaments. The anti-fungal medicaments are azole-type or polyene-type anti-fungal medicaments and based on the effective concentration of the anti-fungal medicaments, the adding ratio of the kaempferol is 0.5 to 16 mu g/ml. Tests show that when the kaempferol and the anti-fungal medicaments such as fluconazole, ketoconazole, miconazole and amphotericin B are used together, not only the anti-fungal effect is guaranteed on the premise of lowering the consumption of the anti-fungal medicaments, but also the anti-fungal medicaments can restore the function of killing the drug-resistant fungi, so that the kaempferol can be used as a synergist of the anti-fungal medicaments. The kaempferol used as the synergist of the anti-fungal medicaments can lower the consumption of the azole-type or polyene-type anti-fungal medicaments so as to reduce the toxic and side effects of the medicaments; and the kaempferol can make the anti-fungal medicaments restore the function of killing the drug-resistant fungi, so that the kaempferol can effectively treat mycotic infection, particularly drug-resistant t mycotic infection, and has quite important clinical application values.

The invention discloses a berberine azole compound shown in general formulas such as I-IV, and a pharmaceutically acceptable salt thereof, and also discloses a preparation method of the compound, which comprises the following steps that: a compound VI and an azole compound HIm or 1H-2-mercaptobenzimidazole are reacted to obtain an intermediate VII or VIII, and then the obtained intermediate is reacted with a compound V to obtain the berberine azole compound shown in general formulas such as I or II; and the compound V and a compound IX or XI are reacted to obtain an intermediate X or XII, and then the obtained intermediate is reacted with the azole compound Him to obtain the berberine azole compound shown in general formulas such as III or IV. The berberine azole compound has a certain inhibitory activity on Gram-positive bacteria, Gram-negative bacteria and fungi, the anti-bacterial activity of part of the compounds is equal to or even stronger than that of chloramphenicol or norfloxacin, the antifungal activity of part of the compounds is equal to or even stronger than that of fluconazole, and the berberine azole compound can be used for preparing anti-microbial drugs.

The invention discloses antifungal application of fraxetin, belonging to the technical field of medicines. In-vitro experiments show that fraxetin has relatively good inhibition effect to the fungi, is capable of restoring the effect of an antifungal drug, namely fluconazole to drug-resistant fungi and therefore can be taken as the antifungal drug and a synergist for the antifungal drug. Accordingto the antifungal application, the new use of fraxetin is opened up, fraxetin is used as the antifungal drug and the synergist for the antifungal drug, a new candidate drug is provided for the fungustreatment, and the antifungal effects of existing drugs are improved. Under the conditions that clinical fungus drug resistance becomes common increasingly and the drug resistance level becomes serious increasingly, the effect of an antifungal drug to the drug-resistant fungi is restored, and the use dosage of the antifungal drug is reduced, so that the medical expense of a patient is saved, andthe toxic and side effects of the drugs are reduced.

The invention relates to a freeze-drying composition of a posaconazole prodrug and a preparation method and application of the freeze-drying composition of the posaconazole prodrug. The freeze-drying composition has the advantages that the freeze-drying composition is high in water solubility, and safety of the freeze-drying composition is guaranteed due to the fact that cyclodextrins auxiliary materials need not to be added during the preparation of the freeze-drying composition; the freeze-drying composition is suitable for being used for treating various amphotericin-intolerant or refractory adult invasive fungal infections; the freeze-drying composition is used as a preventive drug for high-risk patients, the freeze-drying composition is applicable to patients above 13 years old and with impaired immunity and especially applicable to patients who have graft versus host disease (GVHD) after hematopoietic stem cell transplant, patients with leukemia and patients with long-term leukopenia due to chemotherapy; compared with control drugs such as fluconazole and itraconazole, the freeze-drying composition can effectively prevent invasive aspergillosis and can lower the mortality related to the invasive fungal infections.

The invention discloses a novel application of honokiol and fluconazole in antifungal cooperation. According to the invention, the fungi are candida albicans. According to the invention, a standard macrodilution drug sensitivity experiment recommended by CLSI is adopted, in vitro sensitivity of honokiol towards clinically separated drug resistant candida albicans is evaluated with systematic methods such as a checkerboard macrodilution method and a time-kill curve method. Also, an in vitro synergistic effect of honokiol and fluconazole in clinic drug resistant fungi resistance is evaluated. Further, with a mice infection and treatment experiment, an in vivo synergistic effect of honokiol and fluconazole in clinic drug resistant fungi resistance is evaluated.

A method of treating or preventing fungal infection, which includes identifying a plant or animal having a fungal infection and administering an effective amount of an anti-fungal composition to the plant or animal to reduce the fungal infection. In a preferred form of the present invention, the antifungal composition is compound 13 or 33 and is combined with an azole compound, such as fluconazole.

The invention discloses a triazole compound. The triazole compound has excellent water solubility. The triazole compound is obtained by introduction of a novel functional group to high efficiency and wide spectrum antifungal compound voriconazole and fluconazole drugs found in the existing clinical application and novel drug development so that the triazole compound greatly improves voriconazole and fluconazole water solubility and reduces drug toxicity.

The invention discloses a pesticide composition containing fluconazole hydroxylamine and prochloraz and application thereof. The pesticide composition comprises effective components; the effective components are fluconazole hydroxylamine and prochloraz; the mass ratio of fluconazole hydroxylamine to prochloraz is 20:1 to 1:20. The invention further discloses the application of the pesticide composition containing fluconazole hydroxylamine and prochloraz to the treatment of fusarium head blight. The pesticide composition disclosed by the invention has the benefits that the respective potential drug resistance risk of gibberella zeae to fluconazole hydroxylamine and prochloraz is reduced; after fluconazole hydroxylamine and prochloraz are combined, an obvious synergistic effect exists between fluconazole hydroxylamine and prochloraz; the effect on prevention and treatment of the fusarium head blight is significant.

The invention relates to a compound fluconazole ointment prepared from fluconazole, neomycinsulphate, vaseline, lanolin, liquid paraffin, stearic acid, span-80, span-85, tween-80, sorbic acid, A-200, A-380, glycerol, DMF, ethyl acetate and distilled water. The invention uses new-generation triazole type medicine fluconazole to substitute nystatin in erfuling, combines fluconazole and neomycinsulphate to treat deep mycotic infection and has favorable curative effect. The ointment has enlarged antimicrobial spectrum, enhanced bacterium resistance and reduced toxic or side effect and can achieve the effect of deep therapy. Medicine-sensitive and clinical experiments indicate that the invention can effectively control the itch disease of the auditory canals of animals and the infection of mould fungi and microzyme in the skin and the auditory canals, is also effective to the local mycotic infection of dogs and cats and also can treat any possible primary and secondary bacterial infection. The compound fluconazole ointment is applied to the surfaces of the skin and the auditory canals and can effectively relieve inflammatory reactions and itch.

Xanthochymol and garcinol, isoprenylated benzophenones purified from Garcinia xanthochymus fruits, showed multiple activities against fungal biofilms. Both compounds effectively prevented emergence of fungal germ tubes and were also cytostatic, with MICs of 1 to 3 ΞM. The compounds therefore inhibited development of hyphae and subsequent biofilm maturation. Xanthochymol treatment of developing and mature biofilms induced cell death. In early biofilm development, killing had the characteristics of apoptosis. These activities resulted in failure of biofilm maturation and hyphal death in mature biofilms. In mature biofilms, xanthochymol and garcinol caused the death of biofilm hyphae, with 50% effective concentrations (EC₅₀s) of 30 to 50 μM. Additionally, xanthochymol-mediated killing was complementary with fluconazole against mature biofilms, reducing the fluconazole EC₅₀ from greater than 1,024 μg per ml to 13 μg per ml.

The invention relates to the technical field of medicines, in particular to new application of theaflavin as a synergist of antifungal drugs. Through in vitro experiments, when used together with fluconazole, itraconazole, miconazole, ketoconazole and other antifungal drugs, theaflavin can increase therapeutic effect on slight surface and deep fungus infection to some extent and can restore the effect of the antifungal drugs on drug-resisting fungi. Therefore, the theaflavin can be used as the synergist of the antifungal drugs. The invention provides new application for the theaflavin; when used as the synergist of the antifungal drugs, the theaflavin not only can increase the antifungal effect of the drugs, but also can restore the effect of the antifungal drugs on the drug-resisting fungi in the condition that clinic fungal drug resistance is more and more common and drug resistance degree is more and more serious. The application dosage of the antifungal drugs can be reduced, so that medical expenses can be saved for patients, and the toxic and side effects of the drugs are reduced.

An application of the berberine as the synergist of antifungus medicine (fluconazole, ketoconazole, etc) is disclosed.